Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Pancreatic Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumors 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Endometrial Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-menopausal Breast Cancer 1Non-Small Cell Lunch Cancer 1Non Castrate Metastatic Prostate Cancer 1Neoplasms 1Nasopharyngeal Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Solid Tumor 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × NVP-BKM120 × Clear all
NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
18 enrolled
Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡